C. Ola Landgren, Leader of Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“MORE ENCOURAGING NEWS TODAY for the multiple myeloma community: Bristol Myers Squibb has announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel), a potential first-in-class GPRC5D-directed CAR T-cell therapy!
The trial met its primary endpoint of overall response rate (ORR) and its key secondary endpoint of complete response (CR) rate in heavily pretreated patients previously exposed to BCMA-targeted therapy. This is particularly important as modern combinations are creating a rapidly growing population of patients who have already received, and may be resistant to, major therapeutic classes.
This progress builds upon foundational discovery and translational science initiated and led by Dr. Eric Smith and his team, initially at Memorial Sloan Kettering Cancer Center and now at Dana-Farber Cancer Institute. This important work helped establish GPRC5D as a compelling therapeutic target in myeloma and demonstrated the potential of rationally designed GPRC5D-directed CAR T cells (see here).
It is exciting to see discovery science advance toward a potential treatment for patients with resistant disease.
The larger story is how profoundly the field is changing.
Myeloma treatment has evolved from a largely chemotherapy-based approach toward increasingly precise, immune-directed strategies. CAR T-cell therapies, bispecific antibodies, next-generation immune modulators, and alternative targets such as GPRC5D are expanding what may be possible, even following prior BCMA-directed therapy.
The next chapter will not be defined by response alone.
We must determine how deeply treatment eliminates disease, how long immune control is sustained, and why residual cells persist or escape. This is where sensitive minimal residual disease (MRD) testing, integrated with molecular and immune profiling, can help guide treatment selection, sequencing, intensification, and ultimately de-escalation.
At Sylvester Myeloma Institute, University of Miami, Sylvester Comprehensive Cancer Center, we are building toward this future: developing modern immunotherapies, studying immune fitness and resistance, and using MRD to move beyond simply measuring response, toward making residual disease biologically informative and therapeutically actionable.
The future is bright. The ultimate destination is ‘precision intervention’: delivering the right therapy, against the right target, at the right time, guided by the biology of each patient’s disease.”
You can also read:
Arlocabtagene Autoleucel Meets Primary Endpoint in Phase 2 QUINTESSENTIAL Trial for Multiple Myeloma
